Cellectar Biosciences, Inc. (NASDAQ:CLRB) Shares Sold by Nantahala Capital Management LLC

Nantahala Capital Management LLC decreased its stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 2.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,833,325 shares of the biopharmaceutical company’s stock after selling 40,000 shares during the period. Nantahala Capital Management LLC owned 5.11% of Cellectar Biosciences worth $4,583,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. XTX Topco Ltd grew its stake in Cellectar Biosciences by 432.4% during the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 51,413 shares during the last quarter. AIGH Capital Management LLC grew its stake in shares of Cellectar Biosciences by 8.2% in the 2nd quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock valued at $7,590,000 after purchasing an additional 231,270 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Cellectar Biosciences by 146.7% in the first quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock valued at $4,741,000 after purchasing an additional 708,191 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Cellectar Biosciences during the fourth quarter worth $3,817,000. Finally, Rosalind Advisors Inc. raised its position in Cellectar Biosciences by 335.4% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock worth $6,764,000 after buying an additional 2,084,138 shares during the last quarter. 16.41% of the stock is currently owned by institutional investors and hedge funds.

Cellectar Biosciences Price Performance

Cellectar Biosciences stock opened at $2.14 on Tuesday. The stock’s 50 day moving average price is $2.09 and its 200 day moving average price is $2.78. Cellectar Biosciences, Inc. has a 1-year low of $1.82 and a 1-year high of $4.45. The company has a market cap of $76.72 million, a PE ratio of -0.69 and a beta of 0.99.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Cellectar Biosciences to a “sell” rating in a report on Thursday, September 26th.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.